Clinical study AOH1996 and osimertinib combination as an innovative approach to treating Non Small Cell Lung Cancer (NSCLC).
Latest Information Update: 10 Jun 2024
At a glance
- Drugs AOH-1996 (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Jun 2024 New trial record